Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

S. Winski · SciRah

Researcher profile · Semantic Scholar

S. Winski

Share profile

S. Winski — researcher profile on SciRah

h-index: 25
Works: 87
Citations: 3,704

Most-cited papers

NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms.
David Ross, J. Kepa, S. Winski, H. Beall +2 more
2000Chemico-Biological Interactions626 citations
Semantic Scholar
Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor
Jill Hallin, Vickie Bowcut, Andrew Calinisan, David M Briere +26 more
2022Nature Medicine398 citations Open access
Semantic Scholar
Selective RET kinase inhibition for patients with RET-altered cancers
V. Subbiah, V. Velcheti, B. Tuch, K. Ebata +20 more
2018Annals of Oncology380 citations Open access
Semantic Scholar
A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors
A. Drilon, R. Nagasubramanian, J. Blake, N. Ku +30 more
2017Cancer Discovery368 citations Open access
Semantic Scholar
Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1.
D. Siegel, S. M. Mcguinness, S. Winski, David Ross
1999Pharmacogenetics (London)257 citations
Semantic Scholar
Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H:quinone oxidoreductase 1.
D. Siegel, A. Anwar, S. Winski, J. Kepa +2 more
2001Molecular Pharmacology221 citations
Semantic Scholar
Structures of recombinant human and mouse NAD(P)H:quinone oxidoreductases: species comparison and structural changes with substrate binding and release.
Margarita Faig, M. Bianchet, Paul Talalay, Shiuan Chen +3 more
2000Proceedings of the National Academy of Sciences of the United States of America185 citations Open access
Semantic Scholar
A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent.
S. Winski, Robert H. J. Hargreaves, J. Butler, David Ross
1998Clinical Cancer Research110 citations
Semantic Scholar
Subcellular localization of NAD(P)H:quinone oxidoreductase 1 in human cancer cells.
S. Winski, Y. Koutalos, D. Bentley, D. Ross
2002Cancer Research109 citations
Semantic Scholar
Interactions of rat red blood cell sulfhydryls with arsenate and arsenite.
S. Winski, D. Carter
1995Journal of Toxicology and Environmental Health, Part A104 citations
Semantic Scholar
Characterization of a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1 by biochemical, X-ray crystallographic, and mass spectrometric approaches.
S. Winski, M. Faig, M. Bianchet, D. Siegel +6 more
2001Biochemistry96 citations
Semantic Scholar
Structure-based development of anticancer drugs: complexes of NAD(P)H:quinone oxidoreductase 1 with chemotherapeutic quinones.
M. Faig, M. Bianchet, S. Winski, Robert H. J. Hargreaves +4 more
2001Structure82 citations Open access
Semantic Scholar
Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones.
S. Winski, E. Swann, Robert H. J. Hargreaves, Donna L. Dehn +3 more
2001Biochemical Pharmacology81 citations
Semantic Scholar
OSI-930: a novel selective inhibitor of Kit and kinase insert domain receptor tyrosine kinases with antitumor activity in mouse xenograft models.
A. Garton, A. Crew, M. Franklin, A. Cooke +25 more
2006Cancer Research71 citations Open access
Semantic Scholar
Indolequinone antitumor agents: correlation between quinone structure, rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase, and in vitro cytotoxicity.
Howard D. Beall, S. Winski, E. Swann, Anna R. Hudnott +7 more
1998Journal of Medicinal Chemistry70 citations
Semantic Scholar
A Phase 1 Study of Oral ARRY-614, a p38 MAPK/Tie2 Dual Inhibitor, in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes
G. Garcia-Manero, H. Khoury, E. Jabbour, J. Lancet +11 more
2014Clinical Cancer Research51 citations Open access
Semantic Scholar
Mechanisms of action of quinone-containing alkylating agents. I: NQO1-directed drug development.
Howard D. Beall, S. Winski
2000Frontiers in Bioscience45 citations Open access
Semantic Scholar
Pexmetinib: a novel dual inhibitor of Tie-2 and p38 MAPK with efficacy in preclinical models of myelodysplastic syndromes and acute myeloid leukemia
Lohith S. Bachegowda, Kerry A. Morrone, S. Winski, Ioannis Mantzaris +32 more
2016Cancer Research43 citations Open access
Semantic Scholar
Development of a New Isogenic Cell-Xenograft System for Evaluation of NAD(P)H:Quinone Oxidoreductase-Directed Antitumor Quinones
Donna L. Dehn, S. Winski, D. Ross
2004Clinical Cancer Research37 citations Open access
Semantic Scholar
MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas
Lauren E. Stopfer, Nicholas J. Rettko, Owen Leddy, J. Mesfin +5 more
2022bioRxiv36 citations Open access
Semantic Scholar
Differential involvement of caspases in hydroquinone-induced apoptosis in human leukemic hl-60 and jurkat cells.
S. Inayat-Hussain, S. Winski, D. Ross
2001Toxicology and Applied Pharmacology36 citations
Semantic Scholar
NAD(P)H:quinone Oxidoreductase 1 (NQO1): Chemoprotection, Bioactivation, Gene Regulation and Genetic Polymorphisms
D. Ross, J. Kepa, S. Winski, H. Beall +2 more
201033 citations
Semantic Scholar
Abstract 852: ARRY-380, a potent, small molecule inhibitor of ErbB2, increases survival in intracranial ErbB2+ xenograft models in mice
V. Dinkel, Deborah H. Anderson, S. Winski, J. Winkler +2 more
201232 citations
Semantic Scholar
Abstract 2515: Preclinical Development of ARRY-162, A Potent and Selective MEK 1/2 Inhibitor
P. Lee, M. WallaceEli, A. Marlow, Tammie C. Yeh +10 more
201030 citations
Semantic Scholar
162 MEK162 (ARRY-162), a novel MEK 1/2 inhibitor, inhibits tumor growth regardless of KRas/Raf pathway mutations
S. Winski, Deborah H. Anderson, Karyn Bouhana, R. Impastato +6 more
201027 citations
Semantic Scholar
Phase 1 Dose-Escalation/Expansion Study of the p38/Tie2 Inhibitor ARRY-614 in Patients with IPSS Low/Int-1 Risk Myelodysplastic Syndromes
R. Komrokji, A. List, H. Khoury, J. Lancet +9 more
201121 citations
Semantic Scholar
The development of a potent, KDR/VEGFR2-sparing RET kinase inhibitor for treating patients with RET-dependent cancers
B. Brandhuber, J. Haas, B. Tuch, K. Ebata +16 more
201618 citations
Semantic Scholar
Indolequinone antitumor agents: relationship between quinone structure and rate of metabolism by recombinant human NQO1.
Howard D. Beall, Anna R. Hudnott, S. Winski, David Siegel +3 more
1998Bioorganic & Medicinal Chemistry Letters18 citations
Semantic Scholar
Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).
M. Mulvihill, Julie L. C. Kan, P. Beck, M. Bittner +13 more
2005Bioorganic & Medicinal Chemistry Letters17 citations Open access
Semantic Scholar
Effects of parenteral cysteine and glutathione feeding in a baboon model of severe prematurity.
S. Stabler, R. L. Morton, S. Winski, R. Allen +1 more
2000American Journal of Clinical Nutrition17 citations Open access
Semantic Scholar
Sequence of toxic events in arsine-induced hemolysis in vitro : Implications for the mechanism of toxicity in human erythrocytes
S. Winski, D. Barber, L. Rael, D. Carter
199716 citations
Semantic Scholar
Preclinical Data with KIT D816V Inhibitor Bezuclastinib (CGT9486) Demonstrates High Selectivity and Minimal Brain Penetrance
A. Guarnieri, M. Chicarelli, L. Cable, K. Bouhana +5 more
2021Blood9 citations Open access
Semantic Scholar
Abstract #3696: AZD8330 (ARRY-424704): Preclinical evaluation of a potent, selective MEK 1/2 inhibitor currently in phase I trials
E. Wallace, J. Lyssikatos, J. Blake, A. Marlow +19 more
20099 citations
Semantic Scholar
Arsenic Metabolism After Pulmonary Exposure
D. Carter, M. Peraza, F. Ayala-Fierro, E. Casarez +2 more
19999 citations
Semantic Scholar
Abstract 2514: ARRY-162, A Potent and Selective MEK 1/2 Inhibitor, Shows Enhanced Efficacy in Combination with Other Targeted Kinase Inhibitors and with Chemotherapy
R. Woessner, S. Winski, S. Rana, Deborah H. Anderson +2 more
20108 citations
Semantic Scholar
3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.
M. Mulvihill, Julie L. C. Kan, A. Cooke, S. Bhagwat +19 more
2006Bioorganic & Medicinal Chemistry Letters7 citations Open access
Semantic Scholar
Abstract B192: Identification and characterization of highly potent and selective RET kinase inhibitors for the treatment of RET-driven cancers
B. Brandhuber, N. Nanda, Julian Haas, K. Bouhana +16 more
20156 citations
Semantic Scholar
Abstract 1735: The potent and selective MERTK/AXL inhibitor PF-5807/ARRY-067 activates dendritic cells to cross-prime CD8+T cells for anti-tumor activity
J. Wong, Jacqueline Harrison, K. Bouhana, N. Nguyen +12 more
2021Immunology5 citations
Semantic Scholar
The development of LOXO-195, a second generation TRK kinase inhibitor that overcomes acquired resistance to 1st generation inhibitors observed in patients with TRK-fusion cancers
J. Blake, Gabrielle R. Kolakowski, B. Tuch, K. Ebata +14 more
20164 citations
Semantic Scholar
p38MAPK Inhibition Blocks Inflammatory Signaling in Acute Myeloid Leukemia
Alyssa Carey, S. Garg, Megan M. Cleary, David K. Edwards +5 more
20154 citations
Semantic Scholar
Abstract 147: Bezuclastinib is a differentiated KIT inhibitor that exhibits unique selectivity to KIT A-loop mutations, minimal brain penetration, and favorable pharmacokinetic properties in preclinical models
A. Guarnieri, K. Bouhana, L. Cable, Rob Rieger +3 more
2022Cancer Research3 citations
Semantic Scholar
Abstract 4729: The reversible and selective FGFR2/3 inhibitor CGT4859 has superior target coverage of resistance mutations missed by leading FGFR inhibitors
John Fischer, K. Bouhana, R. Brizendine, M. Chicarelli +17 more
2025Cancer Research2 citations
Semantic Scholar
Abstract C196: Identification of first-in-class, highly potent FGFR kinase inhibitors that spare FGFR1
S. Winski, N. Nanda, E. Brown, Tony P. Tang +15 more
20152 citations
Semantic Scholar
Abstract 1782: Human tumor explants are better predictors of clinical trial outcome than cell line xenografts for the KSP inhibitor ARRY-520
M. Humphries, R. Woessner, K. Bouhana, J. Garrus +4 more
20122 citations
Semantic Scholar
Abstract 1798: Identification of pan-Trk inhibitors for the treatment of Trk-driven cancers
K. Bouhana, Á. Gómez, T. Alford, R. Woessner +4 more
20122 citations
Semantic Scholar
Abstract 3004: Preclinical characterization of CGT6297, a novel PI3Kα H1047R mutant-selective inhibitor
Aaron C. Smith, B. Arwood-Levine, Abiezer Blandon, A. Born +36 more
2025Cancer Research1 citations
Semantic Scholar
A Non-covalent KRASG12D Allele Specific Inhibitor Demonstrates Potent Inhibition of KRAS-dependent Signaling and Regression of KRASG12D-mutant Tumors
J. Christensen, Jill Hallin, Vickie Bowcut, Andrew Calinisan +26 more
20221 citations Open access
Semantic Scholar
Abstract P257: Preclinical data identifies bezuclastinib as a differentiated KIT inhibitor with unique selectivity to KIT D816V and minimal evidence of brain penetration
A. Guarnieri, M. Chicarelli, L. Cable, F. Sullivan +3 more
2021Poster Presentations - Proffered Abstracts1 citations
Semantic Scholar
Role of p38 MAPK and Tie2 in the Pathogenesis of MDS and Their Inhibition by Dual Inhibitor ARRY-614.
S. Winski, L. Cable, G. Hogeland, Suzy A. Brown +10 more
20121 citations
Semantic Scholar
Differential activity of ARRY-543, a potent, small molecule inhibitor of EGFR/ErbB-2 compared to lapatanib in in vivo xenograft models
K. Bouhana, Tracy Pheneger, R. Woessner, Gene Tarlton +7 more
20081 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

K. Bouhana×12
Invite
K. Bouhana — researcher profile on SciRah
L. Cable×7
Invite
L. Cable — researcher profile on SciRah
F. Sullivan×6
Invite
F. Sullivan — researcher profile on SciRah
B. Tuch×6
Invite
B. Tuch — researcher profile on SciRah

×6

Invite

K. Ebata — researcher profile on SciRah

Steven W. Andrews×6

Invite

Steven W. Andrews — researcher profile on SciRah

S. Rothenberg×6

Invite

S. Rothenberg — researcher profile on SciRah

Invite

David Ross — researcher profile on SciRah

Invite

P. Lee — researcher profile on SciRah

Invite

R. Woessner — researcher profile on SciRah

Invite

D. Siegel — researcher profile on SciRah

B. Brandhuber×5

Invite

B. Brandhuber — researcher profile on SciRah